| |
LDR-BT (n = 445)
|
IMRT (n = 165)
|
p value
|
|---|
|
Age (year)
|
|
Median (range)
|
71 (48–83)
|
74 (51–84)
|
<0.001 b
|
|
PSA at diagnosis (ng/mL)
|
|
Median (range)
|
7.1 (3.1–43.6)
|
14.1 (2.8–364)
|
<0.001 c
|
|
Biopsy Gleason score
|
|
6 or less
|
245
|
37
| |
|
7
|
173
|
76
| |
|
8–10
|
27
|
52
|
<0.001 a
|
|
Clinical T stage
|
|
T1b/1c
|
0/238
|
2/44
| |
|
T2a/2b/2c
|
143/35/21
|
30/10/5
| |
|
T3a/3b
|
8/0
|
42/32
|
<0.001 a
|
|
Neoadjuvant/Adjuvant ADT
|
|
None
|
267
|
34
| |
|
neo-Ad (+)
|
141
|
24
| |
|
Ad (+)
|
10
|
14
| |
|
neo-Ad (+), Ad (+)
|
27
|
93
|
<0.001 a
|
|
Risk stratification
|
|
Low
|
184
|
17
| |
|
Intermediate
|
201
|
36
| |
|
High
|
60
|
112
|
<0.001 a
|
|
BED (Gy2)
|
|
Median (range)
|
199.2 (120.3–253.2)
|
148 (148–152)
|
<0.001 b
|
|
Follow-up period
|
|
Median (range)
|
75 (3–143)
|
78 (18–125)
|
0.118 b
|
|
Prescribed dose (Gy)
|
|
74
| |
107
| |
|
76
| |
58
| |
|
110
|
141
| | |
|
145
|
97
| | |
|
160
|
207
| | |
|
EBRT
|
|
No
|
300
| | |
|
Yes
|
145
| | |
-
BED biological effective dose, ADT androgen deprivation therapy, Neoad neoadjuvant, Ad adjuvant, EBRT external beam radiation therapy
-
aChi-square test
-
bt-test
-
cMann-Whitney U test
